Table 2

Correlation between in vivo expansion of CD3+CD45RA+/CCR7-effector T cells and tumor recognition by PBMCS (ELISPOT assay) of vaccinated patients

Patient no.% CD45RA+/CCR7-PBMCsaNo. of IFN-γ spots by PBMCs in response to tumor cells
Before vaccinationAfter vaccinationbBefore vaccinationAfter vaccinationb
Group A, increased antitumor T-cell reactivity after vaccination
 01586367 ± 5274 ± 24
 03313752 ± 19236 ± 22
 06546221 ± 289 ± 11
 13495812 ± 859 ± 4
 17344146 ± 8118 ± 6
 18283671 ± 9537 ± 20
 193548321 ± 17698 ± 31
 2026325 ± 239 ± 3
Group B, no increase of antitumor T-cell response after vaccination
 04352810 ± 415 ± 5
 05494836 ± 438 ± 10
 10716556 ± 1259 ± 10
 12353465 ± 460 ± 11
 155856305 ± 17301 ± 32
 16353486 ± 740 ± 8
 265250180 ± 14212 ± 26
  • a Positivity for CD45RA/CCR7 is shown on CD3+-gated PBMCs.

  • b After vaccination refers to PBMCs collected at visit (V) 5 (end of 1st cycle) in all of the listed patients with the exception of patients 1 and 6, tested at V7 (onset of 2nd cycle). All of these patients received the full schedule of vaccination, i.e., eight injections.